Safety and Efficacy of Losmapimod in Patients With Facioscapulohumeral Muscular Dystrophy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Lancet Neurol 2024 May 01;23(5)477-486, R Tawil, KR Wagner, JI Hamel, DG Leung, JM Statland, LH Wang, A Genge, S Sacconi, H Lochmüller, D Reyes-Leiva, J Diaz-Manera, J Alonso-Perez, N Muelas, JJ Vilchez, A Pestronk, S Gibson, NA Goyal, LJ Hayward, N Johnson, S LoRusso, M Freimer, PB Shieh, SH Subramony, B van Engelen, J Kools, OD Leinhard, P Widholm, C Morabito, CM Moxham, D Cadavid, ML Mellion, A Odueyungbo, WG Tracewell, A Accorsi, L Ronco, RJ Gould, J Shoskes, LA Rojas, JG JiangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.